SCHEMBL5052297

SCHEMBL5052297

CNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cc(C(C)C)nn4-c4cccc(F)c4)c3)c(=O)n(C(C)C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ6 P48051 5/20 0.46
KCNJ5 P48544 5/20 0.46
KCNJ3 P48549 5/20 0.46
BRAF P15056 7/20 0.40
RAF1 P04049 5/20 0.40
KRAS P01116 3/20 0.40
KDR P35968 3/20 0.40
MAPK14 Q16539 5/20 0.39
MAPK13 O15264 2/20 0.39
MAPK12 P53778 2/20 0.39
MAPK11 Q15759 2/20 0.39
MAP2K2 P36507 2/20 0.38
MAP2K1 Q02750 2/20 0.38
GAK O14976 1/20 0.36
ABL1 P00519 1/20 0.36
EPHA1 P21709 1/20 0.36
EPHA2 P29317 1/20 0.36
EPHA3 P29320 1/20 0.36
EPHB2 P29323 1/20 0.36
MAPK8 P45983 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062365 0.94 KCNJ6 (0.49) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5060431 0.93 KCNJ6 (0.46) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5062105 0.93 KCNJ6 (0.41) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5054588 0.92 KCNJ6 (0.41) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5052263 0.92 KCNJ6 (0.39) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5052414 0.91 MAPK14 (0.51) BRAFRAF1KRASKDRMAPK14
SCHEMBL5059868 0.90 BRAF (0.49) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5052353 0.89 KCNJ6 (0.42) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5054935 0.89 KCNJ6 (0.42) KCNJ6KCNJ5KCNJ3BRAFRAF1
SCHEMBL5055154 0.88 KCNJ6 (0.39) KCNJ6KCNJ5KCNJ3BRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 KCNJ6 3243/4885KCNJ5 3284/4885KCNJ3 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.